Combining inhibitors of ALK and ROS1 with other agents for the treatment of non–small cell lung cancer

Clinical Advances in Hematology and Oncology

Volumn 13, Issue 5, 2015, Pages 282-284

  Shaw, Alice T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINO 5 [1 (2, 6 DICHLORO 3 FLUOROPHENYL) ETHOXY] N [4 (4 METHYL 1 PIPERAZINYLCARBONYL) PHENYL] 3 PYRIDAZINECARBOXAMIDE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CERITINIB; CRIZOTINIB; PEMETREXED; PF 06463922; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; ROS1 INHIBITOR; RXDX 101; TSR 011; UNCLASSIFIED DRUG; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL] AMINO] 4 PYRIMIDINYL] AMINO] PHENYL] DIMETHYLPHOSPHINE OXIDE; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL FEATURE; DISEASE COURSE; GENE MUTATION; HUMAN; IMMUNOTHERAPY; NON SMALL CELL LUNG CANCER; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENE TRANSLOCATION; GENETICS; INTERVIEW; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 84929168271     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (7)

1. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963-1971.
2. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-2177.
3. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394.
4. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011-1019.
5. Shaw AT, Kim D W, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189-1197.
6. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-fnding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119-1128.
7. Gettinger SN, Shepherd FA, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efcacy, and correlation of outcomes with PD-L1 status [ASCO abstract 8024]. J Clin Oncol. 2014;32(5)(suppl).